Navigation Links
VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:5/15/2008

0 patients, VIA believes that VIA-2291 will be safe and well tolerated in doses currently being administered in the ongoing clinical trials.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase 2 clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond VIA's control and which could materially affect actual results, levels of activity, performance or achievements.

Factors that may cause actual r
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or ... development, marketing and distribution of opioid-related immunotherapies, announced ... with the Securities and Exchange Commission in connection ... be held on Thursday, September 4, 2014, at ... for determining those shareholders eligible to receive notice ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China ... Board of Directors declared a special cash dividend of ... Share ("ADS")) on the Company,s outstanding ordinary shares. The ...
(Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... bumping" transmits significantly fewer bacteria than either handshaking ... of hand-to-hand contact between patients and clinicians, according ... of the American Journal of Infection Control ... Professionals in Infection Control and Epidemiology (APIC). , ... Environmental, and Rural Sciences at Aberystwyth University in ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... the July, 2014, issue of the Journal ... Medicine researchers, sheds new light on the risks ... in the treatment of localized, early-stage esophageal cancer. ... while more invasive, provided significantly better outcomes with ... than endoscopic resection, which had a 76 percent ...
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 ... edition of “Organic Living” on March 12th, a campaign ... an organic lifestyle. In partnership with industry leader ... over 100 Certified Organic teas, the campaign provides readers ... recent years that continues to propel the industry forward ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... -- A Wayne State University study published in the January ... that two influential early studies of cellphone use and crash ... cellphones while driving. In this new study, Richard Young, ... Psychiatry and Behavioral Neurosciences in the School of Medicine, examined ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) ... may one day also prove useful in combating serious cases ... Journal of Infectious Diseases finds that patients hospitalized with ... a statin, compared with their peers who weren,t taking one ...
... Institute for Operations Research and the Management Sciences (INFORMS) ... Society Frank P. Ramsey Medal to Dr. Don N. ... market leading provider of web-based financial analytics and performance ... health systems to enhance their financial planning, budgeting, and ...
... by some as being a potent stimulant, but the debate ... of expert opinions capture the scope of this ongoing debate ... Caffeine Research , a quarterly peer-reviewed journal from Mary Ann ... www.liebertpub.com/jcr . Led by Journal of Caffeine Research ...
... Lyon has developed an animal model carrying a mutation of the ... can no longer induce the death of the cancer cells. This ... treatment that aims to reactivate the dying of cancer cells. ... in the 11th December 2011 issue of the journal Nature ...
... face a steep learning curve to get used to new ... before new total knee replacement procedures are as safe and ... operations using a new device in a hospital are 48 ... undergoing an operation to fit a prosthesis previously used in ...
Cached Medicine News:Health News:Wayne State study shows early research on cellphone conversations likely overestimated crash risk 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2Health News:A gene that protects against colorectal cancers 2Health News:Patients at risk of knee joint complications when new technology is used 2
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... REMstar Plus with C-Flex combines ... and the comfort of C-Flex.With ... REMstar Plus with C-Flex offers ... deliver sleep therapy by taking ...
... a display, ramp capabilities and ... has features that make set-up ... meter records the number of ... four hours - giving you ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Medicine Products: